Global Transdermal Drug Delivery Systems Market Research Report
- Report Code: TR 1000
- Publish Date: Upcoming
The global transdermal drug delivery market, mainly driven by ‘patent cliffs’, increased incidence of chronic diseases, increasing competition, improving patient compliance, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies, was valued at $13.5 billion in 2013 and is expected to reach $21.7 billion by 2018, at a CAGR of 11.1% from 2013 to 2018.
The report analyzes the market in terms of segments such as active transdermal drug delivery and passive transdermal drug delivery.
The U.S. is the world’s largest pharmaceuticals market. It is the world leader in biopharmaceutical research, with 80% of the world’s research & development in biotechnology being conducted by U.S.-based firms. According to the Bureau of Labor Statistics, U.S.A, the pharmaceutical sector employed approximately 272,000 people, and spent $67.4 billion on research & development in 2010. Thus, the well-established pharmaceutical industry in the U.S. is driving the growth of the drug delivery market in the region.
The key drivers for the drug delivery market in North America are the robust pharmaceutical industry, large number of pharmaceutical companies and drug delivery technology providers, and the increasing number of collaborations and partnerships between technology providers and pharmaceutical companies. In addition, an increased demand for self-administration and home healthcare devices, and increasing applications of inhalers, transdermal patches and transmucosal systems for chronic disease areas such as migraine, diabetes, cancer pain, and asthma, have boosted the growth of the market in North America. Healthcare reforms in the U.S. are expected to impact the North American drug delivery market.
Europe holds the second position, in terms of value, in the global pharmaceutical market. The European pharmaceutical market was valued at $228 billion in 2011, accounting for 26.8% of the global market. The industry invested nearly $36500 million in R&D in 2011, provided direct employment to 660,000 Europeans, and generated three to four times more employment indirectly. However, the pharmaceutical markets in the five major European countries, namely, Germany, France, the U.K., Italy, and Spain, grew at an average rate of 2.6% in 2011, due to the overall current grim economic conditions in Europe and the increasing competition from emerging nations.
The pharmaceutical markets in India and China are growing rapidly, owing to low costs and favorable regulatory environments. The Indian pharmaceutical market was ranked 4th, in terms of volume, and 15th, in terms of value, in 2011. This market is expected to reach $20 billion by 2015. The Chinese pharmaceutical market was ranked third-largest, by value, at $64 billion and is expected to become the second-largest by 2015, with this market being projected to grow at a CAGR of over 20%.
In 2012, Asia held a share of 15.0% in the global drug delivery market and was valued at $21.71 billion. It is projected to grow at a CAGR of 12.6% from 2012 to 2017, to reach $39.35 billion by 2017. The major factors propelling the Asian market include the saturation of the Western markets and the economic downturn in the U.S. and Europe. Furthermore, expansion of the Asian region, increase in disposable incomes, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases are expected to drive the growth of the pharmaceutical market in this region. As a result, the Asian oral drug delivery market is expected to grow significantly during the period under consideration.
The report also provides an extensive competitive landscaping of the leading companies operating in this market. The main companies in the market include Novartis, Johnson & Johnson, 3M Company, and Noven, among others. Furthermore, segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options:
Along with the market data, customize the MMM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and deep dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment-wise)
- Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and sub-segment levels
- End-user adoption rate analysis of the products (segment-wise and country-wise)
- Comprehensive coverage of product approvals, pipeline products, and product recalls
Pharmacists’ Forum
- Fast turn-around analysis of pharmacists’ responses to market events and trends
- Pharmacists’ opinions about products from different companies
- Pharmacists’ qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- A comprehensive study of customers’ perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- An analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
Global Passive Transdermal Drug Delivery Market The Global Passive Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $12.27 billion in 2013 and expected to be $20.59 billion by 2018, growing at a CAGR of 10.9 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
Active Active and Microfluidics, Smart Pill Technology (SPT) and Passive adds up to... |
Upcoming |
|
|
Matrix System Matrix System and Reservoir System adds up to total Passive market.... |
Upcoming |
|
|
Reservoir System Reservoir System and Matrix System adds up to total Passive market.... |
Upcoming |
|
|
Microporation Microporation and Iontophoresis adds up to total Active market. ... |
Upcoming |
|
|
Iontophoresis Iontophoresis and Microporation adds up to total Active market. ... |
Upcoming |
|
|
North American Transdermal Drug Delivery Systems Market The North American Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $7.6 billion in 2013 and expected to be $12.7 billion by 2018, growing at a CAGR of 10.9%. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
European Transdermal Drug Delivery Systems Market The European Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $3.6 billion in 2013 and expected to be $5.8 billion by 2018, growing at a CAGR of 9.9 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
Asian Transdermal Drug Delivery Systems Market The Asian Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $1.5 billion in 2013 and expected to be $3.0 billion by 2018, growing at a CAGR of 14.8 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
North American Active Transdermal Drug Delivery Devices Market The North American Active Transdermal Drug Delivery Devices Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $712 million in 2013 and expected to be $1339 million by 2018, growing at a CAGR of 13.5 %. The Transdermal Drug Delivery Devices Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
European Active Transdermal Drug Delivery Devices Market The European Active Transdermal Drug Delivery Devices Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $353 million in 2013 and expected to be $633 million by 2018, growing at a CAGR of 12.4 %. The Transdermal Drug Delivery Devices Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
Asian Active Transdermal Drug Delivery Devices Market The Asian Active Transdermal Drug Delivery Devices Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $109 million in 2013 and expected to be $188 million by 2018, growing at a CAGR of 11.6 %. The Transdermal Drug Delivery Devices Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
North American Passive Transdermal Drug Delivery Market The North American Passive Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $6.85 billion in 2013 and expected to be $11.33 billion by 2018, growing at a CAGR of 10.6 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
European Passive Transdermal Drug Delivery Market The European Passive Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $3.27 billion in 2013 and expected to be $5.19 billion by 2018, growing at a CAGR of 9.6 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
Asian Passive Transdermal Drug Delivery Market The Asian Passive Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $1.40 billion in 2013 and expected to be $2.82 billion by 2018, growing at a CAGR of 15.0%. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
